Edition:
India

argenx SE (ARGX.OQ)

ARGX.OQ on NASDAQ Stock Exchange Global Select Market

229.65USD
1:01am IST
Change (% chg)

$-1.45 (-0.63%)
Prev Close
$231.10
Open
$230.31
Day's High
$234.47
Day's Low
$228.98
Volume
34,806
Avg. Vol
64,434
52-wk High
$272.74
52-wk Low
$103.75

Latest Key Developments (Source: Significant Developments)

Argenx Announces Closing Of Global Offering
Tuesday, 2 Jun 2020 

June 1 (Reuters) - argenx SE ::REG-ARGENX ANNOUNCES CLOSING OF GLOBAL OFFERING.GROSS PROCEEDS FROM GLOBAL OFFERING WERE APPROXIMATELY $862.5 MILLION.  Full Article

Argenx: Underwriters' Exercise Option To Purchase Additional ADSs
Friday, 29 May 2020 

May 29 (Reuters) - ARGENX SE ::ARGENX ANNOUNCES FULL EXERCISE OF UNDERWRITERS’ OPTION TO PURCHASE ADDITIONAL ADSS.SAYS UNDERWRITERS OF ITS PREVIOUSLY ANNOUNCED GLOBAL OFFERING OF ORDINARY EXERCISED THEIR OPTION TO PURCHASE 548,777 ADDITIONAL ADSS IN FULL ON SAME TERMS AND CONDITIONS AS GLOBAL OFFERING.THIS OPTION EXERCISE BRINGS ANTICIPATED TOTAL GROSS PROCEEDS FROM GLOBAL OFFERING TO ABOUT $862.5 MILLION FROM SALE OF AGGREGATE OF 4,207,292 ORDINARY SHARES.CLOSING OF GLOBAL OFFERING, INCLUDING WITH RESPECT TO THE ADSS SUBJECT TO OPTION, IS EXPECTED TO OCCUR ON JUNE 1, 2020, SUBJECT TO CUSTOMARY CLOSING CONDITIONS.  Full Article

Argenx Announces Positive Topline Results From Phase 3 ADAPT Trial Of Efgartigimod
Tuesday, 26 May 2020 

May 26 (Reuters) - ARGENX SE ::ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 3 ADAPT TRIAL OF EFGARTIGIMOD IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS.TRIAL MET PRIMARY ENDPOINT (P ˂0.0001).WELL-TOLERATED; SAFETY PROFILE COMPARABLE TO PLACEBO.BASED ON THESE RESULTS, ARGENX PLANS TO SUBMIT A BIOLOGICS LICENSE APPLICATION (BLA) TO U.S. FOOD AND DRUG ADMINISTRATION (FDA) BY END OF 2020.  Full Article

Argenx Announces Efgartigimod Phase 2 Trial Results
Wednesday, 11 Dec 2019 

Dec 11 (Reuters) - ARGENX SE ::ANNOUNCED ON TUESDAY RESULTS FROM THE COMPLETED PHASE 2 CLINICAL TRIAL OF ITS FCRN ANTAGONIST, EFGARTIGIMOD.EFGARTIGIMOD WAS WELL-TOLERATED AND SHOWED A CORRELATION OF REDUCED IGG LEVELS, INCREASED PLATELET COUNTS AND REDUCED BLEEDING IN ITP PATIENTS.EFGARTIGIMOD HAS DEMONSTRATED A FAVORABLE TOLERABILITY PROFILE AND THE ABILITY TO DRIVE ENCOURAGING RESPONSE RATES - CMO.PHASE 3 PROGRAM OF EFGARTIGIMOD IN ITP ON TRACK TO INITIATE THIS MONTH.PHASE 3 ADAPT TRIAL OF IV EFGARTIGIMOD IS ONGOING IN GMG WITH DATA EXPECTED IN H2 2020.PHASE 2 PROOF-OF-CONCEPT TRIAL OF IV EFGARTIGIMOD IS ONGOING IN PV AND DATA ARE EXPECTED IN H1 2020.PHASE 2 PROOF-OF-CONCEPT TRIAL OF SC EFGARTIGIMOD IN CIDP IS EXPECTED TO START BEFORE THE END OF 2019.  Full Article

Argenx: Additional ADSs Purchase Brings Proceeds To Around $557 Mln From Global Offering
Friday, 8 Nov 2019 

Nov 8 (Reuters) - Argenx Se ::ARGENX ANNOUNCES FULL EXERCISE OF UNDERWRITERS’ OPTION TO PURCHASE ADDITIONAL ADSS.THIS OPTION EXERCISE BRINGS ANTICIPATED TOTAL GROSS PROCEEDS FROM GLOBAL OFFERING TO APPROXIMATELY $557 MILLION FROM SALE OF AN AGGREGATE OF 4,600,000 ORDINARY SHARES.THIS OPTION EXERCISE BRINGS ANTICIPATED TOTAL GROSS PROCEEDS FROM GLOBAL OFFERING TO APPROXIMATELY $557 MILLION (APPROXIMATELY EUR 502 MILLION).MORGAN STANLEY, COWEN, BOFA SECURITIES AND EVERCORE ACTED AS JOINT BOOKRUNNING MANAGERS FOR OFFERING.KEMPEN ACTED AS LEAD MANAGER FOR OFFERING AND WOLFE CAPITAL MARKETS AND ADVISORY ACTED AS CO-MANAGER.  Full Article

Argenx Q1 Total Operating Income Up At 40.0 Million Euros
Thursday, 9 May 2019 

May 9 (Reuters) - ARGENX SE ::Q1 TOTAL OPERATING INCOME EUR 40.0 MILLION VERSUS EUR 6.9 MILLION YEAR AGO.Q1 TOTAL COMPREHENSIVE PROFIT EUR 6.7 MILLION VERSUS LOSS OF EUR 17.7 MILLION YEAR AGO.CASH, CASH EQUIVALENTS AND CURRENT FINANCIAL ASSETS TOTALED €961.6 MILLION ON MARCH 31, 2019, COMPARED TO €564.6 MILLION ON DECEMBER 31, 2018.PHASE 3 ADAPT CLINICAL TRIAL, INCLUDING ONE-YEAR OPEN-LABEL EXTENSION STUDY, IS ONGOING FOR TREATMENT OF GENERALIZED MYASTHENIA GRAVIS WITH TOPLINE DATA EXPECTED IN 2020.Q1 REVENUE EUR 36.5 MILLION VERSUS EUR 5.6 MILLION YEAR AGO.PHASE 2 PROOF-OF-CONCEPT CLINICAL TRIAL ONGOING FOR TREATMENT OF PEMPHIGUS VULGARIS; DATA EXPECTED IN 2020.PHASE 2 CLINICAL TRIAL FOR TREATMENT OF CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY EXPECTED TO START IN SECOND HALF OF 2019.PHASE 1 CLINICAL TRIAL IN HEALTHY VOLUNTEERS PLANNED WITH ENHANZE SC FORMULATION OF EFGARTIGIMOD AS PART OF COLLABORATION WITH HALOZYME ANNOUNCED IN FEBRUARY 2019.FOR THE THREE MONTHS ENDED MARCH 31, 2019, FINANCIAL INCOME AMOUNTED TO €3.5 MILLION VERSUS €0.5 MILLION LAST YEAR.  Full Article

Argenx 9-Mth IAS 18 Operating Loss Widens To EUR ‍​49.1 Million
Thursday, 25 Oct 2018 

Oct 25 (Reuters) - ARGENX SE ::9-MONTH IAS 18 OPERATING LOSS EUR ‍​49.1 MILLION VERSUS LOSS OF EUR 13.5 MILLION YEAR AGO.CASH AND CASH EQUIVALENTS AT END PERIOD EUR 582.3‍​ MILLION VERSUS EUR 161.7 MILLION YEAR AGO.9-MONTH TOTAL COMPREHENSIVE LOSS IAS 18 EUR 38.3 MILLION VERSUS LOSS OF EUR 16.5 MILLION YEAR AGO.9-MONTH IAS 18 REVENUE EUR ‍​17.9 MILLION VERSUS EUR 28.4 MILLION YEAR AGO.  Full Article

Argenx Raises About $300.6 Millionin U.S. Public Offering
Saturday, 22 Sep 2018 

Sept 21 (Reuters) - ARGENX SE ::REG-ARGENX ANNOUNCES CLOSING OF U.S. PUBLIC OFFERING FOR GROSS PROCEEDS OF APPROXIMATELY $300.6 MILLION.REG-ARGENX ANNOUNCES CLOSING OF U.S. PUBLIC OFFERING FOR GROSS PROCEEDS OF APPROXIMATELY $300.6 MILLION.PRICE TO PUBLIC OF $86.50 PER ADS.GRANTED UNDERWRITERS AN OPTION TO PURCHASE UP TO AN ADDITIONAL 521,250 ADSS, REPRESENTING 15% OF ADSS SOLD.OPTION CAN BE EXERCISED DURING 30-DAY PERIOD COMMENCING SEPTEMBER 18, 2018..  Full Article

ArgenX Reports Positive Topline Results From Phase 2 Proof-Of-Concept Trial Of Efgartigimod In Primary Immune Thrombocytopenia
Monday, 17 Sep 2018 

Sept 17 (Reuters) - ARGENX SE ::REG-ARGENX REPORTS POSITIVE TOPLINE RESULTS FROM PHASE 2 PROOF-OF-CONCEPT TRIAL OF EFGARTIGIMOD IN PRIMARY IMMUNE THROMBOCYTOPENIA.FAVORABLE SAFETY AND TOLERABILITY CONSISTENT WITH EFGARTIGIMOD CLINICAL TRIALS TO DATE.CLINICALLY MEANINGFUL PLATELET COUNT IMPROVEMENTS SHOWED CLEAR SEPARATION FROM PLACEBO AT INCREASING RESPONSE THRESHOLDS.PLAN TO ADVANCE ITP PROGRAM INTO PHASE 3 DEVELOPMENT.CIDP ANNOUNCED AS FOURTH INDICATION FOR EFGARTIGIMOD.ALSO EXPECTS TO INITIATE A PHASE 2 TRIAL IN ITP USING A SUBCUTANEOUS FORMULATION OF EFGARTIGIMOD.ANNOUNCED PLANS TO INITIATE A PHASE 2 PROOF-OF-CONCEPT TRIAL OF EFGARTIGIMOD (IV) IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) H1 2019.  Full Article

Argenx Receives Feedback From Japan's PMDA On Phase 3 Clinical Trial
Wednesday, 29 Aug 2018 

Aug 29 (Reuters) - ARGENX SE ::REG-ARGENX RECEIVES FEEDBACK FROM JAPAN'S PMDA ON PHASE 3 CLINICAL TRIAL AND REGULATORY PATHWAY FOR EFGARTIGIMOD IN GENERALIZED MYASTHENIA GRAVIS.DATA FROM PLANNED GLOBAL PHASE 3 REGISTRATION TRIAL, IF POSITIVE, TO SERVE AS BASIS TO SUBMIT FOR MARKETING AUTHORIZATION IN JAPAN.PLANS TO INITIATE GLOBAL PHASE 3 REGISTRATION TRIAL OF EFGARTIGIMOD IN GMG BEFORE END OF 2018.EXPECTS DATA FROM PLANNED GLOBAL PHASE 3 REGISTRATION TRIAL, IF POSITIVE, WILL SERVE AS BASIS TO SUBMIT FOR MARKETING AUTHORIZATION IN JAPAN..GLOBAL PHASE 3 TRIAL EXPECTS TO ENROLL APPROXIMATELY 150 PATIENTS WITH GMG, INCLUDING PATIENTS FROM JAPAN AS WELL AS NORTH AMERICA AND EUROPE.DATA, IF POSITIVE, MAY SERVE AS BASIS FOR BIOLOGICS LICENSE APPLICATION IN U.S. BASED ON FEEDBACK FROM FDA.PATIENTS CAN ROLL OVER INTO AN OPEN-LABEL EXTENSION STUDY FOR A PERIOD OF ONE YEAR.  Full Article

BRIEF-Argenx Announces Closing Of Global Offering

* GROSS PROCEEDS FROM GLOBAL OFFERING WERE APPROXIMATELY $862.5 MILLION Source text for Eikon: Further company coverage: